Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Testicular germ-cell tumour

Oncology and palliative care · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Torsion or unstable metastatic disease

Acute testicular pain remains torsion until excluded, while bulky germ-cell cancer can cause airway, caval, brain or haemorrhagic compromise.

Action: Use immediate urological exploration for suspected torsion without delaying for tumour markers, and stabilise metastatic emergencies with the germ-cell centre because precipitous chemotherapy can cause tumour lysis or pulmonary haemorrhage in heavy choriocarcinoma burden.

Synopsis

Treat a solid intratesticular mass as cancer until proved otherwise, measure markers before inguinal orchidectomy, avoid trans-scrotal biopsy and deliver risk-adapted surveillance, chemotherapy or retroperitoneal treatment with fertility and cure central.

  • Painless intratesticular mass is a pivotal clue in Testicular germ-cell tumour: A firm unilateral lump, change in consistency or diffuse enlargement is the common presentation and needs urgent ultrasound.
  • Immediate priority in unstable Testicular germ-cell tumour: Use immediate urological exploration for suspected torsion without delaying for tumour markers, and stabilise metastatic emergencies with the germ-cell centre because precipitous chemotherapy can cause tumour lysis or pulmonary haemorrhage in heavy choriocarcinoma burden.
  • Scrotal ultrasound is used early to distinguish an intratesticular solid lesion from epididymal, cystic or inflammatory pathology. A solid vascular intratesticular mass is malignant until assessed; ultrasound of the contralateral testis documents baseline and additional lesions.
  • AFP, hCG and LDH before orchidectomy refines the next decision because aFP elevation excludes pure seminoma regardless of initial label; normal markers do not exclude either seminoma or non-seminomatous cancer.
  • Use markers and inguinal surgery: Take AFP, hCG and LDH before surgery, assess the contralateral testis and arrange urgent referral to the germ-cell pathway.
  • Choose surveillance or adjuvant risk reduction: For seminoma, consider surveillance or risk-adapted carboplatin; avoid routine radiotherapy where modern pathways favour lower late toxicity.
  • A major avoidable harm is infertility and hypogonadism; Baseline dysgenesis, orchidectomy, chemotherapy and retroperitoneal surgery can impair sperm, testosterone, sexual health and body image.
  • A common diagnostic trap is epididymal cyst or spermatocele: A separate fluctuant extratesticular lesion is usually benign, but examination uncertainty warrants ultrasound.

Key red flags

A painless firm intratesticular lump or enlarged testis persists despite lack of constitutional symptoms.

Acute testicular pain and swelling could be torsion and requires immediate surgical assessment.

Gynaecomastia, infertility or testicular atrophy accompanies a suspicious lesion.

Back pain, cough, haemoptysis, neck nodes or weight loss suggests retroperitoneal or distant spread.

Very high hCG with lung metastases and haemoptysis raises concern for choriocarcinoma syndrome.

A patient with a solitary testis or future fertility wishes is about to undergo orchidectomy or gonadotoxic chemotherapy.

Thoracic disease

Cough, dyspnoea or haemoptysis suggests lung or mediastinal spread and can become critical with high-volume choriocarcinoma.

Investigation priorities

01
Scrotal ultrasoundFirst step

Distinguish an intratesticular solid lesion from epididymal, cystic or inflammatory pathology.

Management branches

MassUse markers and inguinal surgery

Examination or ultrasound identifies a suspicious solid intratesticular lesion.

  1. Take AFP, hCG and LDH before surgery, assess the contralateral testis and arrange urgent referral to the germ-cell pathway.
  2. Offer sperm banking before orchidectomy when a solitary testis or fertility context makes this important and delay is safe.
  3. Perform radical inguinal orchidectomy without trans-scrotal biopsy, then obtain expert pathology including all germ-cell components and local stage.

Key medicines

BEP chemotherapyA standard 21-day good-risk regimen gives bleomycin 30,000 international units IV on days 1, 8 and 15, etoposide 100 mg/m² IV on days 1–5 and cisplatin 20 mg/m² IV on days 1–5 for 3 cycles.Assess lungs, renal function, hearing, neuropathy and fertility; provide hydration, antiemesis and neutropenic-sepsis advice, and avoid compromising curative dose intensity without germ-cell expert input.
EP chemotherapy when bleomycin is unsuitableFor good-risk metastatic disease when bleomycin is contraindicated, a standard alternative is etoposide 100 mg/m² IV and cisplatin 20 mg/m² IV on days 1–5 every 21 days for 4 cycles.Requires full renal, marrow, hearing, neurological, antiemetic and hydration support; it is a specialist substitution, not a reason to omit a whole treatment component casually.
Open full textbook →Answer 2 questions
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • European Association of Urology testicular cancer guidelineCurrent professional guidance used in UK specialist practice for testicular cancer.
  • NHS England cancer programmeSpecialist multidisciplinary cancer services and timely treatment pathways in England.
  • Royal College of Pathologists cancer datasetsUK pathology sampling, staging, margin and molecular reporting standards.
  • BNF bleomycin, etoposide, cisplatin and carboplatinUK prescribing, contraindication and monitoring information for bleomycin, etoposide, cisplatin and carboplatin.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom